Comprehensive Comparison of Enzymatic and Bisulfite DNA Methylation Analysis in Clinically Relevant Samples

Strategic Insights -

Research conducted at AstraZeneca has provided new insights into the analysis of DNA methylation in clinically relevant samples. A team of investigators, led by Daniel L. Karl, has compared two methods of DNA methylation analysis, bisulfite conversion and enzymatic methylation sequencing, using commercially available assays in patient samples and cell lines. The study aimed to assess the technical differences between the two methods and evaluate their performance in clinically relevant samples. The research concluded that enzymatic methylation sequencing outperformed bisulfite conversion in key sequencing metrics, demonstrating higher estimated counts of unique reads, reduced DNA fragmentation, and higher library yields. However, enzymatic conversion produced inferior methylation array data.

Key Takeaways:

  • Enzymatic methylation sequencing outperformed bisulfite conversion in key sequencing metrics, including estimated counts of unique reads, DNA fragmentation, and library yields.
  • Enzymatic conversion produced higher estimated counts of unique reads (450,000 vs. 300,000) and had reduced DNA fragmentation compared to bisulfite conversion.
  • The enzymatic method showed higher library yields, enabling the development of robust clinical sample pipelines, including targeted sequencing in cfDNA (cancer-free DNA).
  • Bisulfite and enzymatic methods were highly concordant, with a correlation coefficient of 0.95 between the two methods.
  • The study used clinically relevant patient samples, including formalin-fixed paraffin-embedded (FFPE) and circulating free plasma DNA (cfDNA).
  • The research also reported data from a multi-arm experiment comprising controlled reference material and clinically relevant samples.

Statistics:

  • Estimated counts of unique reads: enzymatic methylation sequencing (450,000) vs. bisulfite conversion (300,000).
  • DNA fragmentation: enzymatic conversion showed reduced DNA fragmentation compared to bisulfite conversion.
  • Library yields: enzymatic conversion outperformed bisulfite conversion, enabling the development of robust clinical sample pipelines.
  • Correlation coefficient between bisulfite and enzymatic methods: 0.95.

Sources:

  • Comprehensive comparison of enzymatic and bisulfite DNA methylation analysis in clinically relevant samples. Clinical Epigenetics, 2025;17(1):156.